Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Martin C Muller"'
Autor:
Javier Pinilla-Ibarz, Jorge E. Cortes, Dong-Wook Kim, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F Apperley, H. Jean Khoury, John F. Dipersio, Daniel J DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Muller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D Turner, Frank G Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M Goldman, Neil P. Shah, Hagop M. Kantarjian, Moshe Talpaz
Publikováno v:
Blood. 122:4007-4007
Background Ponatinib is a potent oral pan–BCR-ABL tyrosine kinase inhibitor (TKI) that has demonstrated significant clinical activity in heavily pretreated CP-CML pts. A multivariate analysis of CP-CML pts in the PACE trial found significant associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::195f398f467382f45ec674e885119189
https://doi.org/10.1182/blood.v122.21.4007.4007
https://doi.org/10.1182/blood.v122.21.4007.4007
Autor:
Hagop M. Kantarjian, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Muller, Carlo Gambacorti-Passerini, Stephane Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John Goldman, Neil Shah, Jorge E. Cortes, The PACE Study Group
Publikováno v:
Blood. 120:915-915
Abstract 915 Background: Many patients (pts) with advanced Ph+ leukemias experience failure of all currently available tyrosine kinase inhibitors (TKIs) targeting BCR-ABL and have limited treatment options. Ponatinib is a potent pan-BCR-ABL inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adeee0026e4126672d4a77608133f848
https://doi.org/10.1182/blood.v120.21.915.915
https://doi.org/10.1182/blood.v120.21.915.915
Autor:
Wiltrud Haaß, Helga Kleiner, Christel Weiß, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Rüdiger Hehlmann, Wolf-Karsten Hofmann, Alice Fabarius, Wolfgang Seifarth, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, German CML Study Group
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0129648 (2015)
Unbalanced (major route) additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid leukemia (CML) indicate an increased risk of progression and shorter survival. Moreover, newly arising ACA under imatinib treatment and clonal evolution
Externí odkaz:
https://doaj.org/article/f121bb6eca144f35b1cf7854cf9ad6dc
Autor:
Wiltrud Haaß, Helga Kleiner, Martin C Müller, Wolf-Karsten Hofmann, Alice Fabarius, Wolfgang Seifarth
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0133769 (2015)
ESPL1/Separase, an endopeptidase, is required for centrosome duplication and separation of sister-chromatides in anaphase of mitosis. Overexpression and deregulated proteolytic activity of Separase as frequently observed in human cancers is associate
Externí odkaz:
https://doaj.org/article/0ae70782c5b54ec98a47e9f9b5b718c0